Regulatory Challenges in Addressing Illegal Land Use in Residential Property Transactions
International Journal of Law Analytics · 30.05.2026 · 4 (2) · 211-218
DOI: 10.59890/ijla.v4i2.223 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Law Analytics, online erschienen am 30.05.2026. Verfasst von Mospa Darma. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Illegal land use in residential property transactions has become a major legal issue in developing countries due to rapid urbanization, weak institutional coordination, and fragmented regulations. Practices such as unauthorized land conversion, overlapping ownership claims, and fraudulent land certification undermine legal certainty and sustainable urban governance. This study analyzes regulatory challenges in addressing illegal land use and evaluates the effectiveness of existing legal frameworks. Using a normative juridical method with statutory and conceptual approaches, the study finds that regulatory fragmentation, corruption, weak law enforcement, and administrative inefficiency significantly contribute to illegal land practices. The study concludes that integrated land governance reform and stronger institutional accountability are essential to improve legal certainty and sustainable residential property governance.
Zitieren
APA
Darma, M. (2026). Regulatory Challenges in Addressing Illegal Land Use in Residential Property Transactions. International Journal of Law Analytics, 4(2), 211-218. https://doi.org/10.59890/ijla.v4i2.223
Vancouver
Darma M. Regulatory Challenges in Addressing Illegal Land Use in Residential Property Transactions. International Journal of Law Analytics. 2026;4(2):211-218. doi:10.59890/ijla.v4i2.223
BibTeX
@article{Darma2026,
author = {Darma, Mospa},
title = {Regulatory Challenges in Addressing Illegal Land Use in Residential Property Transactions},
journal = {International Journal of Law Analytics},
year = {2026},
volume = {4},
number = {2},
pages = {211--218},
doi = {10.59890/ijla.v4i2.223}
}
EUVIMED